Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Infection Risk in Lymphoproliferative Diseases (LPD) Treated with Targeted Drugs. Geltamo Real-Life Experience

Blood (2020) 136 (Supplement 1): 37–40.

https://doi.org/10.1182/blood-2020-134729

Published: 2020

Journal Articles

Mesenchymal Stromal Cells for Refractory Acute Graft-Versus-Host Disease By Compassionate Use Provide Comparable Results to Those of Phase II Clinical Trials

Alvaro Veiga, MD, Alba Redondo, MD, Miriam López-Parra, MD, Olga López-Villar, MD, Eva Villarón, Maria Díez-Campelo, MD PhD, Daniel Rivera, MD, Natalia Espinosa, MD, Nerea Arratibel, MD, Mónica Baile, MD, Estefania Pérez-López, MD, Mónica Cabrero, MD, Ana A. Martín, MD, Lourdes Vázquez, MD, Lucía López Corral, MD, Dolores Caballero, MD PhD, Consuelo Del Cañizo, MDPhD, Fermin Sanchez-Guijo, MD PhD

Blood (2017) 130 (Supplement 1): 1981.

https://doi.org/10.1182/blood.V130.Suppl_1.1981.1981

Published: 2017

Journal Articles

CCR6, IL7R, FAS and Madcam-1 Single Nucleotide Polymorphisms Are Associated with Higher Incidence of Infections in Allogeneic Stem-Cell Transplant from a Related Donor after a Reduced Intensity Conditioning Regimen: A Multicenter Experience

Blood (2017) 130 (Supplement 1): 3208.

https://doi.org/10.1182/blood.V130.Suppl_1.3208.3208

Published: 2017

Journal Articles

Usefulness of Thrombopoietin Receptor Agonists for Thrombocytopenia after Allogeneic Stem Cell Transplantation. An Eight-Year Single Center Experience

Daniel Rivera, MD, Jose Maria Bastida, MDPhD, Lucia Lopez Corral, PhD MD, Fermin Sanchez-Guijo, MD PhD, Lourdes Vázquez, MD, Monica Cabrero, MD, Estefania Pérez-López, MD, Miriam López-Parra, MD, Ana A. Martín, MD, Javier Carrillo, MD, Alejandro Avendaño, MD, Alvaro Veiga, MD, Monica Baile, MD, Nerea Arratibel, MD, Dolores Caballero, MD PhD, Consuelo Del Cañizo, MDPhD, Jose Ramon González-Porras, MDPhD

Blood (2017) 130 (Supplement 1): 3222.

https://doi.org/10.1182/blood.V130.Suppl_1.3222.3222

Published: 2017

Journal Articles

Hemorrhagic Cystitis in Haploidentical Hematopoietic STEM CELL Trasplant: Retrospective Study and Comparison with a NON-Haploidentical DONOR Transplant Group

Nerea Arratibel, Monica Cabrero, Estefania Perez, Oriana Lopez, Lucia Lopez, Ana A. Martin, Alvaro Veiga, Monica Baile, Veronica Gonzalez, Felix Lopez, Oscar Ferre, Luis García, Dolores Caballero, MD PhD, Lourdes Vazquez, MD, Maria-Victoria Mateos, MD PhD

Blood (2016) 128 (22): 3418.

https://doi.org/10.1182/blood.V128.22.3418.3418

Published: 2016

Journal Articles

An International Multicenter Comparative Analysis of Tacrolimus Plus Sirolimus with or without Antithymocyte Globulin As Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation

Mohamed A. Kharfan-Dabaja, MD, Rocio Parody, MD, Janelle Perkins, PharmD, Oriana Lopez-Godino, MD, Lucia Lopez-Corral, MD, Lourdes Vazquez, MD, Dolores Caballero, MD, Jose Falantes, MD, Jamie Shapiro, PharmD, Guillermo Orti, MD, Pere Barba, MD, David Valcárcel, MD PhD, Alber Esquirol, MD, Rodrigo Martino, MD PhD, Jose Luis Piñana, MD, Carlos Solano, MD, Joseph A Pidala, MD, PhD, Claudio Anasetti, MD, Jose A. Perez-Simon, MD, PhD

Blood (2015) 126 (23): 3142.

https://doi.org/10.1182/blood.V126.23.3142.3142

Published: 2015

Journal Articles

Strategies for Graft Versus Host Disease Prophylaxis after Reduced-Intensity Conditioning Transplantation: Combination of Sirolimus Plus Tacrolimus Allows to Obtain the Best Outcome

Rocío Parody, MDPhD, Dolores Caballero, Martinez Carmen, MD PhD, Rodrigo Martino, MD PhD, Carlos Solano, Pere Barba, MD, Lucía López-Corral, MD PhD, Oriana Lopez Godino, MD, Lourdes Vazquez, MD, Montserrat Rovira, MD PhD, Francesc Fernandez-Avilés, Albert Esquirol, MD, Irene García Cadenas, José Luís Piñana, David Valcarcel, MD PhD, Francisco J. Marquez-Malaver, Jose Antonio Perez-Simón, MDPhD

Blood (2014) 124 (21): 1165.

https://doi.org/10.1182/blood.V124.21.1165.1165

Published: 2014

Journal Articles

Minimal Residual Disease Monitoring after Reduced Intensity Conditioning (RIC) Allogeneic Transplantation: May Help To Individualize Post-Transplant Immunotherapeutic Strategies.

Maria Diez-Campelo, MD, PhD, Jose A. Perez-Simon, MD, PhD, Jose J. Perez, Dolores M. Caballero, MD, PhD, Belen Vidriales, MD, PhD, Miguel Alcoceba, Lourdes Vazquez, MD, PhD, Marcos Gonzalez, MD, PhD, Consuelo M. Canizo, MD, PhD, Consuelo M. Lopez-Berges, MD, PhD, Jesus Lopez-Fidalgo D, J.F. San Miguel, MD, PhD

Blood (2005) 106 (11): 5397.

https://doi.org/10.1182/blood.V106.11.5397.5397

Published: 2005

Journal Articles

Minimal Residual Disease (MRD) Evaluation by Flow Cytometry in Acute Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation.

Maria-Belen Vidriales, MD, PhD, Jose J. Pérez, Consuelo López-Berges, MD, PhD, Norma C. Gutierrez, MD, PhD, Juana Ciudad, PhD, Lourdes Vazquez, MD, PhD, Consuelo del Cañizo, MD, PhD, Joaquín Díaz-Mediavilla, MD, PhD, Javier Fernández-Calvo, MD, Fernando Ramos, MD, PhD, María Jesús Rodriguez, MD, PhD, María José Calmuntia, MD, PhD, Alberto Orfao, MD, PhD, Jesús San Miguel, MD, PhD

Blood (2004) 104 (11): 1103.

https://doi.org/10.1182/blood.V104.11.1103.1103

Published: 2004

NARROW

Infection Risk in Lymphoproliferative Diseases (LPD) Treated with Targeted Drugs. Geltamo Real-Life Experience

Mesenchymal Stromal Cells for Refractory Acute Graft-Versus-Host Disease By Compassionate Use Provide Comparable Results to Those of Phase II Clinical Trials

CCR6, IL7R, FAS and Madcam-1 Single Nucleotide Polymorphisms Are Associated with Higher Incidence of Infections in Allogeneic Stem-Cell Transplant from a Related Donor after a Reduced Intensity Conditioning Regimen: A Multicenter Experience

Usefulness of Thrombopoietin Receptor Agonists for Thrombocytopenia after Allogeneic Stem Cell Transplantation. An Eight-Year Single Center Experience

Hemorrhagic Cystitis in Haploidentical Hematopoietic STEM CELL Trasplant: Retrospective Study and Comparison with a NON-Haploidentical DONOR Transplant Group

An International Multicenter Comparative Analysis of Tacrolimus Plus Sirolimus with or without Antithymocyte Globulin As Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation

Strategies for Graft Versus Host Disease Prophylaxis after Reduced-Intensity Conditioning Transplantation: Combination of Sirolimus Plus Tacrolimus Allows to Obtain the Best Outcome

Minimal Residual Disease Monitoring after Reduced Intensity Conditioning (RIC) Allogeneic Transplantation: May Help To Individualize Post-Transplant Immunotherapeutic Strategies.

Minimal Residual Disease (MRD) Evaluation by Flow Cytometry in Acute Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only